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Apurinic/apyrimidinic endonuclease (APE) is a key enzyme involved in DNA base excision repair (BER) that is often expressed at
elevated levels in human cancers. Pancreatic cancer cells treated with the nucleoside analogue gemcitabine (20,2 0-difluoro-
20deoxycytidine) showed increases in APE/redox effector factor (ref-1) protein levels (approximately two-fold for Panc-1 and six-fold
for MiaPaCa-2), with corresponding increases in endonuclease activity. These results suggested that the activation of APE/ref-1 might
be an adaptive response that contributes to gemcitabine resistance by facilitating BER. To test this hypothesis, we examined the
effects of disrupting APE/ref-1 using antisense on gemcitabine toxicity. Antisense oligonucleotides decreased protein levels three-fold
in MiaPaCa-2 and five-fold in Panc-1 in comparison to controls, associated with reduced endonuclease activity. Combination
treatments with antisense oligonucleotides and gemcitabine partially suppressed the increase in APE/ref-1 activity seen in cells
exposed to gemcitabine alone. While clonogenic assays showed only slight decreases in colony formation in cells treated with either
antisense oligonucleotides or gemcitabine alone, the combination with APE/ref-1 antisense resulted in a 2-log enhancement of
gemcitabine toxicity in Panc-1 cells. Overall these findings suggest that APE/ref-1 plays a significant role in gemcitabine resistance in
some pancreatic cancer cells, and support the further investigation of novel treatments that target this protein.
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There are over 20000 apurinic/apyrimidinic (AP) sites formed per
cell per day making it one of the most common forms of DNA
damage (Evans et al, 2000; Kelley and Parsons, 2001). Abasic sites
can arise due to spontaneous and chemically initiated hydrolysis
through various conditions such as exposure to ionising radiation,
oxidative stress or cytotoxic agents. The persistence of these abasic
sites in DNA can lead to a halt in DNA replication, mutations and
an overall loss in genetic stability.
The DNA base excision repair (BER) pathway is involved in
maintaining DNA integrity through the removal and replacement
of abasic sites (Evans et al, 2000). Once the damaged base has been
identified by DNA glycosylases, the base is removed leaving an
abasic site, which is hydrolysed by the apurinic/apyrimidinic
endonuclease (APE) at position 50 to the abasic site, leaving a 30
hydroxyl and an abasic deoxyribose-5-phosphate. The abasic site
is removed by deoxyribose phosphatase, then DNA polymerase b
and DNA ligase I or DNA ligase III/XRCCI replaces the nucleotide
and closes the gaps between the newly synthesised nucleotide and
the strand. Aside from BER, the APE protein is also involved in
maintaining various transcription factors in their active reduced
states such as AP-1, NF-kB, HIF-1 and p53 (Hirota et al, 1997; Ema
et al, 1999; Ueno et al, 1999). Therefore, APE is also commonly
referred to as redox effector factor (ref-1) protein.
APE/ref-1 levels have been shown to be elevated in various types
of cancers such as cervical, prostate, ovarian and germ cell
tumours (Xu et al, 1997; Herring et al, 1998; Moore et al, 2000;
Kelley et al, 2001; Robertson et al, 2001). Previous studies have
shown that a decrease in APE/ref-1 protein renders mammalian
cells sensitive to methyl methanesulphonate and hydrogen
peroxide (Walker et al, 1994), while radioresistance of human
cervical tumours directly correlates with increased APE/ref-1
expression (Herring et al, 1998). Following exposure to irradiation
and oxidative stress, tumour cells showed elevated APE/ref-1
protein levels (Herring et al, 1998; Ramana et al, 1998; Silber et al,
2002), while overexpression of APE/ref-1 in testicular cancer
resulted in bleomycin resistance (Robertson et al, 2001).
Attempts to create APE/ref-1 knockout mice (APEX / ) were
embryonically lethal, suggesting that APE/ref-1 is crucial for
embryonic development (Xanthoudakis et al, 1996; Ludwig et al,
1998). Heterozygous APE/ref-1 mice (APEXþ/ ) were viable but
abnormally sensitive to oxidative stress and prone to cancer
development (Meira et al, 2001).
Pancreatic ductal adenocarcinoma is the fifth leading cause of
cancer death in North America. It is highly resistant to
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sconventional cytotoxic agents, and is almost 100% lethal.
Currently, the only active agent appears to be a chain terminator,
gemcitabine (20,2 0-difluoro-20deoxycytidine), and there is an
urgent need to develop new and more effective treatment
(Abbruzzese, 2002; Haller, 2003). In this paper, we demonstrate
that treatment of pancreatic cancer cells with gemcitabine
significantly induces APE/ref-1 protein expression and endonu-
clease activity, and that the suppression of APE/ref-1 activity by
antisense oligonucleotides produces a large increase in chemo-
sensitivity in gemcitabine-treated Panc-1 cells.
MATERIALS AND METHODS
Cell lines and culture
The MiaPaCa-2 and Panc-1 human pancreatic cell lines (American
Type Culture Collection, Rockville, MD, USA) were maintained in
Dulbecco’s medium with L-glutamine, 0.1mgml
 1 kanamycin and
10% foetal bovine serum (FBS) (GibcoBRL, Burlington, Ontario,
Canada). Cells were grown at 371C and 5% CO2 in a humidified
atmosphere. Cell cultures were passaged routinely once a week and
re-established from frozen stock every 2 months.
Western blot analysis
Protein was extracted from cells treated with lysis buffer
containing protease inhibitor cocktail tablets (Roche Canada,
Mississauga, Ontario, Canada), 50mM HEPES (pH¼8.0), 10%
glycerol, 1% Triton X-100, 150mM NaCl, 1mM EDTA, 1.5mM
MgCl2, 100mM NaF, 10mM NaP2O7 H2O) and centrifuged
at 14000r.p.m. at 41C for 10min. Samples were loaded in a
12% polyacrylamide gel, with 1  running buffer and allowed
to run in a gel chamber (Bio-Rad Laboratories, Mississauga,
Ontario, Canada). Following transfer to nitrocellulose membranes,
these membranes were incubated in 1:1000 primary APE/ref-1
antibody (Novus Biologicals, Littleton, CO, USA) and probed
with 1:2000 goat anti-mouse monoclonal antibody (Amersham
Biosciences, Baie d’Urfe ´, Quebec, Canada). Membranes were
exposed to ECL and developed on film (Kodak, New Haven, CT,
USA), then stained and destained with amido black to determine
protein loading.
Flow cytometry analysis
Cells were adjusted to 1 10
6 cellsml
 1 and fixed with 2%
formaldehyde for 10min at 371C, followed by 90% ice-cold
methanol for 30min. Prior to antibody staining, cells were rinsed
with 2ml phosphate-buffered saline (PBS) containing 4% FBS.
Based on a preliminary dilution curve showing that this
concentration is saturating, 1:1000 dilution of APE/ref-1 antibody
(Novus Biologicals, Littleton, CO, USA) was added to the pellet for
30min at room temperature, then washed twice in PBS plus 4%
FBS. A goat-anti-mouse FITC-labelled secondary antibody (Caltag
Laboratories, Burlingame, CA, USA) was added to the pellet for
15min at room temperature, and the sample washed twice with
PBS plus 4% FBS and resuspended in 1ml of PBS plus 4% FBS.
Samples were analysed by flow cytometry (Epics Elite; Beckman-
Coulter, Miami, FL, USA) using 488nm excitation and collecting
through a 525nm bandpass filter. To standardise the flow
cytometry results, calibration particles (Rainbow Beads; Spher-
otech Inc., Libertyville, IL, USA) were measured in each sample
run. A calibration curve was generated based on the mean
fluorescence values for the Rainbow Beads, as illustrated in
Figure 1, and used to convert the mean fluorescence of the samples
into the number of FITC molecules per cell.
Gemcitabine treatment
Gemcitabine was obtained from Eli Lilly & Co (Indianapolis, IN,
USA). Exponentially growing cells were plated at B10
5 cellsml
 1
in T-25cm
2 flasks, and drug added at desired concentrations to the
medium and incubated for 24 or 48h. After treatment, cells were
washed, harvested and counted for the preparation of cell lysates,
or fixed for flow cytometry analysis.
Transfection of antisense oligonucleotides
Two antisense oligonucleotides were synthesised (ACGT, Toronto,
Ontario, Canada) based on sequences recently published by Silber
et al (2002). One antisense oligonucleotide targeted the transla-
tional start site of APE/ref-1 mRNA, while the other oligonucleo-
tide targeted the exon–intron junction of the pre-mRNA.
Oligonucleotides synthesised in the sense direction were used as
controls. The oligonucleotides were transfected into cells of 60–
70% confluency. In one well of a 12-well plate, 250nM of each of
the oligonucleotides was added along with 12ml of Plus Reagent
(Invitrogen, Burlington, Ontario, Canada) and Opti-MEM media
(Invitrogen, Burlington, Ontario, Canada) adjusted to a total
volume of 100ml and allowed to stand for 15min at room
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Figure 1 APE/ref-1 protein levels in control and gemcitabine-treated
MiaPaCa and Panc-1 monolayers. (A) Representative flow cytometry data
for MiaPaCa cells treated with 60mM gemcitabine for 48h compared to
untreated control, autofluorescence background and calibration beads.
Gated on light scatter to exclude dead cells. (B) APE/ref-1 protein levels in
MiaPaCa and Panc-1 controls and cells treated with 20, 40 and 60 mm
gemcitabine for 48h, expressed as mean equivalent fluorescein (MEFL)
values obtained from the calibration beads. Bars represent means from
three separate experiments7s.e. Stars indicate results that are statistically
significant (Po0.05) with respect to the nontreated samples.
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stemperature. In another well, 4ml of Lipofectamine Reagent was
added to 96ml of Opti-MEM media and allowed to stand for
15min. Precomplexed DNA was combined with the diluted
Lipofectamine reagent and incubated at room temperature for
15min. Growth medium was removed from flasks and DNA–
Plus–Lipofectamine Reagent complexes containing 800ml of fresh
Opti-MEM media was added and mixed gently. Cells were allowed
to incubate at 371Ca t5 %C O 2 for 4h. Opti-MEM was then
removed and replaced with normal growth medium containing
250nM of each of the antisense oligonucleotides.
In order to measure the uptake kinetics for each oligonucleotide
by flow cytometry and to determine the effects of lipofectamine,
the translational start site targeting antisense oligonucleotide was
labelled with FITC and the exon–intron targeting antisense
oligonucleotide was labelled with Cy5.5. The flow cytometry
technique was similar to that for APE/ref-1 protein measurement,
with the additional use of a 633nm HeNe laser to excite Cy5.5.
Purification of APE/ref-1 protein
Human APE/ref-1 wild-type protein was overproduced using the
pGEX-3X (Pharmacia Biotech, Uppsala, Sweden) system utilising
the BamHI 50 and EcoRI 30 restriction sites, obtained from Dr Mark
Kelley (Indiana University). The transformations were performed
using One Shot
s TOP 10 Competent Cells (Invitrogen, Burlington,
Ontario, Canada) with transformed Escherichia coli cells spread on
Luria–Bertani (LB) agar plates containing ampicillin. Colonies
found to contain the transformed plasmid were placed in LB broth
containing 100mgml
 1 ampicillin and incubated overnight at
371C. For batch purification of protein, 200ml of glutathione
sepharose 4B slurry (Amersham Biosciences, Baie d’Urfe ´, Quebec,
Canada) was equilibriated and the bacterial sonicate allowed to
incubate at room temperature for 30min. To sediment the gel,
glutathione elution buffer was added, mixed gently and then
centrifuged at 500g for 5min. The supernatant was then dialysed
for 2h at 41C in 100 volumes of GST. The concentration of the
GST-tagged protein was determined by assuming 1 absorbance
unit at 280nm was equal to 0.5mgml
 1. The purified APE/ref-1
protein was stored in aliquots at  201 and used as the positive
control in the endonuclease assay.
Endonuclease assay
A 26-mer oligonucleotide (IDT Technologies, Coralville, IA, USA)
containing a tetrahydrofuran (F) residue at position 15 was used,
as described by Kelley et al (2001) and Kelley and Parsons (2001).
Following
32P labelling, the oligonucleotide was purified using a
G25 column and then annealed to a complementary oligonucleo-
tide. Based on 2.0 10
5 cells lysed, 1ml of total cell extract was
added to 10ml reaction volume containing 5000c.p.m. of labelled
double-stranded F oligonucleotide in 50mM HEPES, 50mM KCl,
10mM MgCl2,2 m M DTT, 1mgml
 1 bovine serum albumin and
0.05% Triton X-100, adjusted to pH 7.5. Reactions were allowed to
proceed for 5min in a 371C water bath and stopped by adding 4ml
of 96% formamide, 10mM EDTA and bromophenol blue. The
positive control was the purified APE/ref-1 protein (0.5–2.0mg),
and the negative control consisted of cells treated with the BER
inhibitor methoxyamine hydrochloride 33mM (Sigma-Aldrich
Canada Ltd, Oakville, Ontario, Canada) mixed in buffer containing
50mM KPO4, (pH 7.1), and exposed to double-stranded oligonu-
cleotide for 15min in a 371C water bath prior to adding lysate.
Samples were separated with a 15% polyacrylamide gel containing
7 M urea and exposed to a Molecular Dynamics Phosphoimager to
measure the intensities of the substrate and product bands, and to
film overnight for visualisation. Calculation of the fraction of
product formed was based on Fraction of product formed¼Area
product/(Area productþArea substrate).
Clonogenic assay
Aliquots of 10
5 cells were taken from cell suspensions treated with
antisense or sense oligonucleotides and/or gemcitabine and diluted
serially in growth medium post-treatment, plated in six-well cell
culture plates (Gibco BRL, Burlington, Ontario, Canada) at final
cell densities of 10
4,1 0
3 and 10
2 cellswell
 1. After 7 and 12 days of
incubation at 371C in 95% air and 5% CO2 for MiaPaCa-2 and
Panc-1, respectively, medium was removed and plates allowed to
air dry. Colonies were counter-stained with methylene blue in 70%
ethanol for 5min and counted.
Statistical analysis
Statistical analyses were performed with Jandel Sigma Stat
software, Version 2.0. For comparisons between treatments, the
analysis of variance test of equal variance or Kruskal–Wallis was
applied with the Dunnett’s method. A P-value of a¼0.05 indicated
statistical significance.
RESULTS
Gemcitabine effects on APE/ref-1 protein
Preliminary experiments showed that both cell lines maintained
490% viability, based on flow cytometric assessment of light
scatter and propidium iodide exclusion, following exposure to
up to 60mM gemcitabine for up to 48h. To examine whether
gemcitabine was able to induce APE/ref-1 levels, MiaPaCa-2
and Panc-1 cells were treated with a range of gemcitabine concen-
trations for 24 or 48h, and APE/ref-1 protein levels measured
using Western blot or flow cytometry. Preliminary experiments
showed that these two techniques gave comparable results.
However, the flow cytometry method was more rapid and easier
to standardise and was therefore used for most experiments. As
shown in Figure 1, the two cell lines showed similar basal levels
of APE/ref-1, and each showed a gemcitabine dose-dependent
increase following 48h of continuous treatment. Relative to
untreated controls, MiaPaCa-2 cells treated with 40 and 60mM of
gemcitabine showed four- and six-fold increases in APE/ref-1
protein expression (P¼0.012 and 0.003, respectively), while
Panc-1 cells treated with 60mM of gemcitabine showed a two-fold
increase (P¼0.047). Smaller increases in APE/ref-1 were also
seen after 24h treatment with gemcitabine in both cell lines (data
not shown).
In vitro assessment of APE/ref-1 endonuclease activity of
gemcitabine-treated cells
To examine the effects on endonuclease activity, MiaPaCa-2 and
Panc-1 cells were treated with various concentrations of gemcita-
bine for 48h, then lysed and assayed for catalytic activity. More 14-
mer product was formed, with a corresponding decrease in 26-mer
substrate, at increasing concentrations of gemcitabine (Figure 2A).
Both cell lines showed dose-dependent increases in endonuclease
activity following treatment with gemcitabine (Figure 2B). Using
60mM of gemcitabine, the levels were six-fold greater (Po0.05)
than control for MiaPaCa-2 and two-fold greater (Po0.05) than
control for Panc-1. MiaPaCa-2 and Panc-1 monolayers were
treated with gemcitabine for 48h and samples for protein
expression and endonuclease activity were taken from the same
flask to determine the correlation between endonuclease activity
and APE/ref-1 protein expression. As shown in Figure 3, these
values were highly correlated in both MiaPaCa-2 (r¼0.951) and
Panc-1 (r¼0.999).
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sUptake kinetics of fluorescently labelled antisense
oligonucleotides
The antisense oligonucleotide targeting the translational start site
of APE/ref-1 mRNA was labelled with FITC, while the other
antisense oligonucleotide targeting the exon–intron junction of
APE/ref-1 pre-mRNA was labelled with Cy5.5. Subcellular localisa-
tion of the antisense oligonucleotides was examined using
fluorescence microscopy and the translational start site targeting
antisense was found in the cytoplasm, while the exon–intron
targeting antisense oligonucleotide was located in the nucleus
(Figure 4). Preliminary experiments using flow cytometry showed
very low levels of fluorescently labelled oligonucleotide uptake in
the control cells relative to lipofectamine-treated cells (data not
shown). With lipofectamine, the uptake of both antisense
oligonucleotides appeared to saturate at concentrations above
250nM. Based on the flow cytometry calibration beads, the mean
fluorescence values for cells transfected at this concentration
correspond to approximately 4 10
5 oligonucleotides cell
 1 for
the FITC-labelled construct. A concentration of 250nM of each
antisense oligonucleotide was chosen for future experiments.
Effects of APE/ref-1 antisense on protein expression and
endonuclease activity
Both cell lines were transfected with antisense or sense oligonu-
cleotides and APE/ref-1 protein levels were analysed 12, 24, 48 and
72h post-transfection. Using both Western blot and flow
cytometry, there were statistically significant decreases in protein
levels detected after 24h of transfection with MiaPaCa-2 decreas-
ing three-fold (Po0.001) and Panc-1 decreasing four-fold
(Po0.001). After 48h post-transfection, the APE/ref-1 levels had
substantially recovered. The level of endonuclease activity was
assessed in cell lysates, obtained from the same flasks as the
samples taken for protein measurements. As illustrated in Figure 5,
a reduction in the amount of 14-mer product formed vs substrate
was seen 24h post-transfection, with recovery of endonuclease
activity at 48h, consistent with the decrease in protein levels.
Treatment with oligonucleotides that were synthesised in the sense
direction had no significant effects on APE/ref-1 protein levels or
endonuclease activity.
APE/ref-1 protein and endonuclease activity in
gemcitabine-treated cells: effects of antisense
To examine if APE/ref-1 antisense was able to suppress the
increases in protein levels and endonuclease activity seen following
treatment with gemcitabine, experiments involving the treatment
of cells with both antisense oligonucleotides and gemcitabine were
performed. Both MiaPaCa-2 and Panc-1 cell lines were transfected
with antisense or sense oligonucleotides for 12 and 24h with some
samples receiving an additional 24h treatment of 20mM of
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Figure 2 Endonuclease activity present in gemcitabine-treated cells. (A)
Film images of 26-mer substrate vs 14-mer product in MiaPaCa and Panc-1
cells after various doses of gemcitabine for 48h. Positive controls consisted
of purified recombinant APE/ref-1 protein and negative controls included
the BER inhibitor methoxyamine. (B) Range of gemcitabine concentrations
vs the fraction of 14-mer product formed. Stars indicate results that are
statistically significant (Po0.05) with respect to the nontreated samples.
The concentration of gemcitabine is expressed as mM. All values are means
of three independent experiments7s.e.
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Figure 3 Relationship between APE/ref-1 protein level vs endonuclease
activity postgemcitabine exposure. MiaPaCa (diamonds) and Panc-1
(squares) cells were treated with various doses of gemcitabine for 48h.
Samples from the same flask were collected and assessed using both flow
cytometry and endonuclease assay. Points represent mean values from
three separate experiments and error bars are standard error of the mean;
r¼0.951 (MiaPaCa) and 0.999 (Panc-1).
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sgemcitabine. There was a decrease in APE/ref-1 induction when
the cells were transfected with antisense prior to gemcitabine
exposure, relative to the samples treated with gemcitabine alone or
gemcitabine plus oligonucleotides synthesised in the sense
direction (Figure 6A). Similarly, endonuclease activity was lower
in the cells transfected with antisense oligonucleotides prior to
gemcitabine treatment vs the cells treated with gemcitabine alone
(Figure 6B).
In vitro sensitivity of APE/ref-1 antisense-treated Panc-1
and MiaPaCa-2 cells to gemcitabine
Colony-forming assays were performed on both cell lines treated
with antisense or sense oligonucleotides and gemcitabine. The
MiaPaCa-2 cells were found to be more gemcitabine sensitive than
Panc-1 in the clonogenic assay in preliminary experiments, and the
dose was therefore reduced to 5mM for MiaPaCa-2. Samples were
also treated with gemcitabine for 24h prior to transfection with
antisense to determine whether the order of administration
influenced clonogenic survival. As shown in Figure 7, lower
numbers of colonies were formed by MiaPaCa-2 and Panc-1 cells
treated with antisense alone, gemcitabine alone or the combina-
tion, when compared to cells treated with sense oligonucleotides or
untreated controls (Po0.05). Gemcitabine-treated Panc-1 cell lines
showed a 2-log decrease in colony formation when the cells were
pretreated for 24h with antisense oligonucleotides compared to
cells treated with gemcitabine alone or in combination with the
sense oligonucleotides (Figure 7A). Despite the suppression of
APE/ref-1 activity in MiaPaCa-2 cells treated with antisense, the
effects on gemcitabine sensitivity relative to the sense construct
were much smaller and not statistically significant (Figure 7B).
DISCUSSION
In this study, we show that gemcitabine is capable of inducing
APE/ref-1 levels in two pancreatic cancer cell lines, MiaPaCa-2 and
Panc-1. The increase in APE/ref-1 protein levels was closely
correlated with an increase in endonuclease activity, suggesting
that APE/ref-1 is the predominant endonuclease enzyme in these
cells. These results suggest the existence of a cellular response that
might facilitate the repair of gemcitabine-induced DNA damage,
potentially thereby enhancing drug resistance. To investigate this
further, we examined the effects of antisense oligonucleotides
against APE/ref-1 mRNA, using constructs recently described by
Silber et al (2002) and treatment schedules based on initial
experiments that measured the uptake of fluorescence-labelled
Translational start
FITC Cy 5.5
Exon − intron Overlay
Figure 4 Subcellular localisation of fluorescence-labelled antisense oligonucleotides. That targeting the exon–intron junction of APE/ref-1 pre-mRNA is
localised in the nucleus, whereas the translational start is cytoplasmic.
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Figure 5 Endonuclease activity of MiaPaCa and Panc-1 cells treated with
antisense oligonucleotides. The MiaPaCa and Panc-1 cell lines were
exposed to antisense or sense oligonucleotides for various time points.
Cell lysates were collected and analysed using the endonuclease assay.
C – control; AS – antisense; S – sense.
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soligonucleotides. These antisense oligonucleotides were able to
suppress gemcitabine-induced APE/ref-1 activity when given prior
to but not following gemcitabine treatment. We avoided exposure
to gemcitabine immediately following treatment with lipofecta-
mine, and the data shown in Figure 6 were obtained 36 and 48h
following antisense treatment. Since the maximum effect of the
antisense oligonucleotides was seen at 24h, the effects on APE/ref-
1 in combination with gemcitabine might be underestimated.
Panc-1 cells, which were highly resistant to gemcitabine based on
clonogenic assay, showed a large enhancement in gemcitabine
toxicity when treated with APE/ref-1 antisense. This finding of
enhanced sensitivity to a DNA-damaging agent is similar to but
greater than earlier results obtained by Walker et al (1994) using
stable transfectants of the full-length APE/ref-1 antisense and the
more recent results obtained by Silber et al (2002) using
phosphorothioate antisense oligonucleotides. However, although
MiaPaCa-2 cells showed similar responses to those seen in Panc-1
following treatment with gemcitabine and antisense in terms of
APE/ref-1 protein levels and endonuclease activity, the sensitisa-
tion to gemcitabine by the antisense was small and not statistically
significant relative to the sense control.
The effects of gemcitabine on APE/ref-1 protein induction seen
in the present study are greater than those previously reported
involving oxidative stress or g-irradiation (Herring et al, 1998;
Ramana et al, 1998; Silber et al, 2002). However, to our knowledge
this study is the first to address the effects of deoxynucleoside
analogues on APE/ref-1 activity. It should be noted that although
the concentrations of gemcitabine used in these experiments
approximate the peak plasma levels achieved using standard dose
schedules, the continuous exposure for 48h exceeds that seen in
cancer patients. Therefore, it remains to be determined if APE/ref-
1 activity is increased during treatment with gemcitabine in the
clinic. In preliminary experiments, we have found that another
deoxycytidine analogue, cytosine arabinoside (ara-C), is able to
elevate APE/ref-1 levels in OCI/AML-2 leukaemia cells (not
shown), suggesting that this might be a widespread response to
treatment with deoxynucleoside analogues.
Previous studies have demonstrated elevated levels of another
BER protein, DNA ligase I, in MiaPaCa-2 cells treated with ara-C
and gemcitabine (Gandhi et al, 1996; Gandhi et al, 1997). The
enhancement of DNA ligase I protein due to ara-C exposure was
not accompanied by increased DNA synthesis or polymerase
activity. DNA ligase I levels returned to normal as the drug-treated
cells resumed DNA synthesis, thus strongly suggesting the
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Figure 6 APE/ref-1 protein levels (A) and endonuclease activity (B)
post-treatment with antisense/sense oligonucleotide7gemcitabine. (A)
Protein levels. MiaPaCa (dark bars) and Panc-1 (light bars) cells were
treated with antisense or sense oligonucleotides720mM gemcitabine. APE/
ref-1 protein levels were accessed at 12 or 24h post-transfection of
oligonucleotides or 24h post-treatment with gemcitabine. As indicated,
some samples were treated with gemcitabine prior to transfection with
antisense oligonucleotides to determine whether the sequence of
treatment affected outcome. Bars represent three individual experiments,
with error bars representing standard error of the mean. AS – antisense;
S – sense; Gem – gemcitabine.
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Figure 7 Clonogenic survival of (A) Panc-1 and (B) MiaPaCa cells
treated with gemcitabine alone, with antisense (AS) or sense oligonucleo-
tide for 12 or 24h or the combination. Bars represent at least three
individual experiments, with standard error of the mean indicated by the
error bars.
aStatistically significant (Po0.05) compared to control samples.
bStatistically significant (Po0.05) with respect to the gemcitabine-only
treated samples.
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sincreased DNA ligase I levels were involved in repair of DNA
damage caused by ara-C, rather than DNA replication (Sun et al,
2002a,b). Also, it has been previously shown that the antisense
oligonucleotides used in the present paper are able to reduce APE/
ref-1 protein and endonuclease activity in human glioma cells,
with concurrent reduction in resistance towards the alkylating
agents methyl methanesulphonate and temozolomide (Silber et al,
2002). Another study examining the effects of methoxyamine, an
inhibitor of BER through binding of abasic sites, found that this
enhanced sensitivity to temozolomide in human colon cancer
xenografts (Liu et al, 2002). Taken together, these studies suggest
that the BER pathway plays an important role in cancer
chemotherapy resistance, and that suppression of BER might
therefore result in increased chemosensitivity.
The enhancement of APE/ref-1 activity following gemcitabine
treatment suggests that this might be playing a role in the repair of
DNA damage, although we recognise that it is unclear if APE/ref-1
acts on misincorporation of gemcitabine into DNA. The present
series of experiments does not establish that the sensitising effects
of APE/ref-1 antisense is due to suppression of its BER activity,
since APE/ref-1 also acts as a redox regulator of several
transcription factors including NF-kB and AP1 that can promote
cell survival responses (Hirota et al, 1997; Arrigo, 1999; Ueno et al,
1999; Moos et al, 2003). For example, the activation of NF-kB can
occur during treatment with cancer chemotherapy and is believed
to promote drug resistance (Wang et al, 1999; Baldwin, 2001; Arlt
et al, 2003). The increases in APE/ref-1 seen in pancreas cancer
cells during treatment with gemcitabine might augment this NF-kB
response, additional to any effects on BER. The BER and redox
effector activities of APE/ref-1 can be differentially regulated by
phosphate modifications, and each function involves complex
interactions with other cellular proteins (Yacoub et al, 1997; Evans
et al, 2000; Hsieh et al, 2001). The striking difference observed
between the sensitisation of Panc-1 and MiaPaCa-2 cells to
gemcitabine following APE/ref-1 antisense treatment is likely to
be explained on the basis of differences involving these elements,
and further work is needed in this area.
Phosphorothioate antisense olignonucleotides have been devel-
oped as therapeutic agents targeting a number of genes involved in
cancer development, and several are currently undergoing clinical
trial (O’Dwyer et al, 1999; Morris et al, 2002). Using APE/ref-1
antisense, we obtained a two decade decrease in the clonogenic
survival of highly resistant Panc-1 cells treated with gemcitabine.
Although it is not known if clinically achievable gemcitabine levels
can upregulate APE/ref-1 activity in cancer patients, or if selective
targeting of APE/ref-1 would enhance the therapeutic index of
gemcitabine in pancreas cancer patients, they warrant further
investigation including in vivo testing in xenograft models,
examination of other pancreas cancer cell lines and elucidation
of the underlying mechanisms. This work is currently in progress
in our laboratory.
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